In the past week, OTLK stock has gone down by -36.34%, with a monthly decline of -47.13% and a quarterly surge of 217.19%. The volatility ratio for the week is 26.36%, and the volatility levels for the last 30 days are 15.36% for Outlook Therapeutics Inc The simple moving average for the last 20 days is -37.34% for OTLK stock, with a simple moving average of -3.64% for the last 200 days.
Is It Worth Investing in Outlook Therapeutics Inc (OTLK) Right Now?
Moreover, the 36-month beta value for OTLK is 0.85. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy”, 0 as “overweight”, 2 as “hold”, and 0 as “sell”.
The public float for OTLK is 151.89M and currently, short sellers hold a 7.40% of that float. On July 29, 2026, OTLK’s average trading volume was 21.04M shares.
OTLK stock’s latest price update
Outlook Therapeutics Inc (OTLK) has seen a decline in its stock price by -15.12% in relation to its previous close of $1.07. However, the company has experienced a -36.34% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2026-07-28 that Outlook Therapeutics (OTLK) receives both FDA and European approval for LYTENAVA, targeting wet AMD, but faces significant commercialization challenges. I downgrade OTLK to ‘Hold’ due to acute cash constraints and the urgent need for strategic funding or a partnership to support U.S. launch. LYTENAVA offers a lower-cost, ophthalmic bevacizumab alternative in a competitive $8.5B U.S. anti-VEGF retina market, but market capture remains uncertain.
Analysts’ Opinion of OTLK
Many brokerage firms have already submitted their reports for OTLK stocks, with BTIG Research repeating the rating for OTLK by listing it as a “Buy”. The predicted price for OTLK in the upcoming period, according to BTIG Research is $4 based on the research report published on July 27, 2026 of the current year 2026.
OTLK Trading at -21.75% from the 50-Day Moving Average
After a stumble in the market that brought OTLK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.33% of loss for the given period.
Volatility was left at 15.36%, however, over the last 30 days, the volatility rate increased by 26.36%.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OTLK starting from Haddadin Yezan Munther, who purchase 29,000 shares at the price of $0.83 back on Jun 02 ’26. After this action, Haddadin Yezan Munther now owns 66,167 shares of Outlook Therapeutics Inc, valued at $24,145 using the latest closing price.
Sukhtian Ghiath M., the Director of Outlook Therapeutics Inc, purchase 8,539,709 shares at $0.59 during a trade that took place back on May 28 ’26, which means that Sukhtian Ghiath M. is holding 22,092,068 shares at $5,000,000 based on the most recent closing price.
Stock Fundamentals for OTLK
Current profitability levels for the company are sitting at:
- -181.83% for the present operating margin
- -3.61% for the gross margin
The net margin for Outlook Therapeutics Inc stands at -182.98%. The total capital return value is set at 3.56%.
Based on Outlook Therapeutics Inc (OTLK), the company’s capital structure generated -15.05 points at debt to capital in total, while cash flow to debt ratio is standing at -1.73. The debt to equity ratio resting at -0.94. The interest coverage ratio of the stock is -193.21.
Currently, EBITDA for the company is $-63.58 million with net debt to EBITDA at -0.31. When we switch over and look at the enterprise to sales, we see a ratio of 169.99. The receivables turnover for the company is 0.12for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.54.
Conclusion
To wrap up, the performance of Outlook Therapeutics Inc (OTLK) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
